<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37954857</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Evaluation and mechanism study of Pien Tze Huang against EV-A71 infection.</ArticleTitle><Pagination><StartPage>1251731</StartPage><MedlinePgn>1251731</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1251731</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2023.1251731</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) caused by enterovirus A71 (EV-A71) infection, currently lacks specific preventive and therapeutic interventions. Here, we demonstrated that Pien Tze Huang (PZH) could dose-dependently inhibit EV-A71 replication at the cellular level, resulting in significant reductions in EV-A71 virus protein 1 (VP1) expression and viral yields in Vero and human rhabdomyosarcoma cells. More importantly, we confirmed that PZH could protect mice from EV-A71 infection for the first time, with Ribavirin serving as a positive control. PZH treatment reduced EV-A71 VP1 protein expression, viral yields in infected muscles, and improved muscle pathology. Additionally, we conducted a preliminary mechanism study using quantitative proteomics. The results suggested that the suppression of the PI3K/AKT/mTOR and NF-κB signaling pathways may contribute to the anti-EV-A71 activity of PZH. These findings provide strong evidence supporting the potential therapeutic application of PZH for EV-A71 infection management.</AbstractText><CopyrightInformation>Copyright © 2023 Wang, Chen, Wang, Li, Liu, Li, Deng, Dong, Pang, Song, Zhang, Yu and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiqiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fenbei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shicong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development, Zhangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Drug Control, National Institute for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yinghong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Hongbin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jingwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Danqing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dousheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Drug Control, National Institute for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development, Zhangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pien Tze Huang</Keyword><Keyword MajorTopicYN="N">cytokine</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">host</Keyword><Keyword MajorTopicYN="N">multicomponent drug</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList><CoiStatement>Authors SW and JY were employed by Fujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37954857</ArticleId><ArticleId IdType="pmc">PMC10637388</ArticleId><ArticleId IdType="doi">10.3389/fphar.2023.1251731</ArticleId><ArticleId IdType="pii">1251731</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abzug M. J. (2014). The enteroviruses: problems in need of treatments. J. Infect. 68 (1), S108–S114. 10.1016/j.jinf.2013.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2013.09.020</ArticleId><ArticleId IdType="pubmed">24119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman L. J., Brueckner A. J., Doligalski C. T. (2018). The role of mTOR inhibitors in the management of viral infections: a review of current literature. Transplantation 102 (2S), S50–S59. 10.1097/TP.0000000000001777</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000001777</ArticleId><ArticleId IdType="pubmed">29369973</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan G., Yang H., Shi L., Sun W., Sui M., Zhang R., et al. (2014). Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study. PLoS One 9 (11), e112676. 10.1371/journal.pone.0112676</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112676</ArticleId><ArticleId IdType="pmc">PMC4229228</ArticleId><ArticleId IdType="pubmed">25391156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T., Li Y., Fan S., Li W., Wang S., Li S., et al. (2019). Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur. J. Med. Chem. 175, 172–186. 10.1016/j.ejmech.2019.04.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.04.048</ArticleId><ArticleId IdType="pubmed">31082764</ArticleId></ArticleIdList></Reference><Reference><Citation>Heredia A., Le N., Gartenhaus R. B., Sausville E., Medina-Moreno S., Zapata J. C., et al. (2015). Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proc. Natl. Acad. Sci. 112(30), 9412–9417. 10.1073/pnas.1511144112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1511144112</ArticleId><ArticleId IdType="pmc">PMC4522811</ArticleId><ArticleId IdType="pubmed">26170311</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Zhang Y., Zhang X., Chen X., Wang Y., Lu J., et al. (2019). Therapeutic potential of pien-tze-huang: a review on its chemical composition, Pharmacology, and clinical application. Mol. (Basel, Switz. 24 (18), 3274. 10.3390/molecules24183274</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24183274</ArticleId><ArticleId IdType="pmc">PMC6767116</ArticleId><ArticleId IdType="pubmed">31505740</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Xu W., Zhang Y., Liu J., Zhang X., Lin J., et al. (2016). Identification and quantification of the anti-inflammatory constituents in Pian-Tze-Huang by liquid chromatography combined with quadrupole time-of-flight and triple quadrupole mass spectrometry. J. Chromatogr. B 1027, 27–39. 10.1016/j.jchromb.2016.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2016.05.021</ArticleId><ArticleId IdType="pubmed">27240301</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z., Zhou X., Zhang X., Huang L., Sun Y., Cheng Z., et al. (2021). Pien-Tze-Huang, a Chinese patent formula, attenuates NLRP3 inflammasome-related neuroinflammation by enhancing autophagy via the AMPK/mTOR/ULK1 signaling pathway. Biomed. Pharmacother. 141, 111814. 10.1016/j.biopha.2021.111814</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111814</ArticleId><ArticleId IdType="pubmed">34146853</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Zhang R., Wu W., Duan G. (2018). Antiviral and inflammatory cellular signaling associated with enterovirus 71 infection. Viruses 10 (4), 155. 10.3390/v10040155</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10040155</ArticleId><ArticleId IdType="pmc">PMC5923449</ArticleId><ArticleId IdType="pubmed">29597291</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinyan Z., Haixia H., Yun W., Yuchen Z., Liangpu Z., Zhenfeng H. (2017). Pien Tze Huang Gan Bao ameliorates carbon tetrachloride-induced hepatic injury, oxidative stress and inflammation in rats. Exp. Ther. Med. 13 (5), 1820–1826. 10.3892/etm.2017.4174</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.4174</ArticleId><ArticleId IdType="pmc">PMC5443228</ArticleId><ArticleId IdType="pubmed">28565773</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Sage V., Cinti A., Amorim R., Mouland A. J. (2016). Adapting the stress response: viral subversion of the mTOR signaling pathway. Viruses 8 (6), 152. 10.3390/v8060152</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8060152</ArticleId><ArticleId IdType="pmc">PMC4926172</ArticleId><ArticleId IdType="pubmed">27231932</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang C., Shi Q., Yang T., Zhu Q., Tian Y., et al. (2013). Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid. Based Complement. Altern. Med. 2013, 316250. 10.1155/2013/316250</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/316250</ArticleId><ArticleId IdType="pmc">PMC3557643</ArticleId><ArticleId IdType="pubmed">23401711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian B., Cai L., Zhang Z., Lin F., Li Z., Zhang X.-k., et al. (2022). The anti-inflammatory effect of Pien Tze Huang in non-alcoholic fatty liver disease. Biomed. Pharmacother. 151, 113076. 10.1016/j.biopha.2022.113076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113076</ArticleId><ArticleId IdType="pubmed">35550529</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Q., Luo Z., Zeng J., Chen W., Foo S. S., Lee S. A., et al. (2016). Zika virus NS4A and NS4B proteins deregulate akt-mTOR signaling in human fetal neural stem cells to inhibit neurogenesis and induce autophagy. Cell Stem Cell 19 (5), 663–671. 10.1016/j.stem.2016.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.07.019</ArticleId><ArticleId IdType="pmc">PMC5144538</ArticleId><ArticleId IdType="pubmed">27524440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M., Zhu D. (2012). Pien Tze Huang combined with chemotherapy in treatment of advanced colon cancer. Fujian J. Tradit. Chin. Med. 43 (1), 8–9.</Citation></Reference><Reference><Citation>Lin H., Zhou J., Lin K., Wang H., Liang Z., Ren X., et al. (2016). Efficacy of scutellaria baicalensis for the treatment of hand, foot, and mouth disease associated with encephalitis in patients infected with EV71: a multicenter, retrospective analysis. Biomed. Res. Int. 2016, 5697571. 10.1155/2016/5697571</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/5697571</ArticleId><ArticleId IdType="pmc">PMC5093290</ArticleId><ArticleId IdType="pubmed">27840828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.-X., Yu J., Chen Z.-L., Wang S.-C., Hong F., Zhuang Y.-C., et al. (2022). Effect of pien tze huang against EV71. Zhongguo Zhong Yao Za Zhi. 47 (5), 1343–1349. 10.19540/j.cnki.cjcmm.20211117.701</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20211117.701</ArticleId><ArticleId IdType="pubmed">35343163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J. Y., Kung Y. A., Shih S. R. (2019). Antivirals and vaccines for enterovirus A71. J. Biomed. Sci. 26 (1), 65. 10.1186/s12929-019-0560-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0560-7</ArticleId><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Zhong M., Guo C., Komatsu M., Xu J., Wang Y., et al. (2016). Autophagy is involved in regulating influenza A virus RNA and protein synthesis associated with both modulation of Hsp90 induction and mTOR/p70S6K signaling pathway. Int. J. Biochem. Cell Biol. 72, 100–108. 10.1016/j.biocel.2016.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2016.01.012</ArticleId><ArticleId IdType="pubmed">26794463</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z. X., Zhou Z. G. (2006). Clinical study on the treatment of recurrent aphthous ulcer with zhong tong'an combined with dexamethasone. Shanghai Kou Qiang Yi Xue 15 (5), 555–556.</Citation><ArticleIdList><ArticleId IdType="pubmed">17348237</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Z., Ge M., Chen J., Geng Q., Tian M., Qiao Z., et al. (2017). HRS plays an important role for TLR7 signaling to orchestrate inflammation and innate immunity upon EV71 infection. PLoS Pathog. 13 (8), e1006585. 10.1371/journal.ppat.1006585</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006585</ArticleId><ArticleId IdType="pmc">PMC5595348</ArticleId><ArticleId IdType="pubmed">28854257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X., Qiu M., Chen D., Zheng N., Jin Y., Wu Z. (2014). Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. Antivir. Res. 109, 30–41. 10.1016/j.antiviral.2014.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.06.004</ArticleId><ArticleId IdType="pubmed">24971492</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L., Gu X. (2008). Clinical observation of the changes of immune indexes of primary liver cancer treated with Pien Tze Huang and TACE. Jiu Jiang Med. J. 1, 31–33.</Citation></Reference><Reference><Citation>Pathinayake P. S., Hsu A. C., Wark P. A. (2015). Innate immunity and immune evasion by enterovirus 71. Viruses 7 (12), 6613–6630. 10.3390/v7122961</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122961</ArticleId><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinelli D. F., Wakeman B. S., Wagener M. E., Speck S. H., Ford M. L. (2015). Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection. Am. J. Transpl. 15 (10), 2576–2587. 10.1111/ajt.13326</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13326</ArticleId><ArticleId IdType="pmc">PMC5389899</ArticleId><ArticleId IdType="pubmed">25989700</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L. J., Muench H. (1938). A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27 (3), 493–497. 10.1093/oxfordjournals.aje.a118408</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm G. (1955). Pharmacopeia of the People's Republic of China, 1953 edition. Pharm. Zentralhalle Dtschl 94 (5), 173–175.</Citation><ArticleIdList><ArticleId IdType="pubmed">13254321</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M. J., McMinn P., Ooi M. H. (2010). Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10 (11), 778–790. 10.1016/s1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain S. K., Gadnayak A., Mohanty J. N., Sarangi R., Das J. (2022). Does enterovirus 71 urge for effective vaccine control strategies? Challenges and current opinion. Rev. Med. Virol. 32 (4), e2322. 10.1002/rmv.2322</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2322</ArticleId><ArticleId IdType="pubmed">34997684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Cui B., Yan H., Wu S., Wang K., Yang G., et al. (2023). Targeting 7-dehydrocholesterol reductase against EV-A71 replication by upregulating interferon response. Antivir. Res. 209, 105497. 10.1016/j.antiviral.2022.105497</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105497</ArticleId><ArticleId IdType="pubmed">36528172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo T., Yang Y., Yu L., Pan X., Li Y. (2019). Lycorine derivative LY-55 inhibits EV71 and CVA16 replication through downregulating autophagy. Front. Cell Infect. Microbiol. 9, 277. 10.3389/fcimb.2019.00277</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00277</ArticleId><ArticleId IdType="pmc">PMC6692562</ArticleId><ArticleId IdType="pubmed">31448243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Li Y. (2019). Recent progress on functional genomics research of enterovirus 71. Virol. Sin. 34 (1), 9–21. 10.1007/s12250-018-0071-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0071-9</ArticleId><ArticleId IdType="pmc">PMC6420560</ArticleId><ArticleId IdType="pubmed">30552635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H. Q., Jiang J. D., Li Y. H. (2013). Establishment of EV71 animal models with 2-week-old BALB/c mice. Yao Xue Xue Bao 48 (3), 343–346.</Citation><ArticleIdList><ArticleId IdType="pubmed">23724645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye N., Gong X., Pang L.-l., Gao W.-j., Zhang Y.-t., Li X.-l., et al. (2015). Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections. BMC Infect. Dis. 15 (1), 225. 10.1186/s12879-015-0965-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0965-1</ArticleId><ArticleId IdType="pmc">PMC4461975</ArticleId><ArticleId IdType="pubmed">26058678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lam W. P., Lü L., Wang C., Wong Y. W., Lam L. H., et al. (2010). Protective effects and potential mechanisms of Pien Tze Huang on cerebral chronic ischemia and hypertensive stroke. Chin. Med. 5, 35. 10.1186/1749-8546-5-35</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8546-5-35</ArticleId><ArticleId IdType="pmc">PMC2984508</ArticleId><ArticleId IdType="pubmed">20955558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Zhao B., Chen X., Song N., Wu J., Li G., et al. (2018). GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways. Antivir. Res. 153, 39–48. 10.1016/j.antiviral.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.002</ArticleId><ArticleId IdType="pubmed">29425831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Wang X., Zhang Y., Chen L., Hua L., Xu W. (2019). Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis. J. Ethnopharmacol. 244 (C), 111856. 10.1016/j.jep.2019.111856</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2019.111856</ArticleId><ArticleId IdType="pubmed">30959141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong M., Wang H., Yan H., Wu S., Wang K., Yang L., et al. (2022). Effects and mechanism of Aβ1−42 on EV-A71 replication. Virology J. 19 (1), 151. 10.1186/s12985-022-01882-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01882-3</ArticleId><ArticleId IdType="pmc">PMC9485788</ArticleId><ArticleId IdType="pubmed">36127711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong R., Duan Z., Chen Y., Zhen S., Kong M., Xu M. (2017). Clinical study of Pien tze huang in treatment of chronic hepatitis B. Chin. J. Gastroenterol. Hepatol. 26, 1290–1294.</Citation></Reference><Reference><Citation>Zhu J., Zhang D., Wang T., Chen Z., Chen L., Wu H., et al. (2021). Target identification of hepatic fibrosis using Pien Tze Huang based on mRNA and lncRNA. Sci. Rep. 11 (1), 16980. 10.1038/s41598-021-96459-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96459-5</ArticleId><ArticleId IdType="pmc">PMC8379174</ArticleId><ArticleId IdType="pubmed">34417500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>